Genmab — Maj 2019

[E_L]

to @GeorgeBest

[Solsen]

Der er slet ikke resultater på effektivitet i Ena. Men hvis de udvider med fase 2a forsøg så må de have set noget.

[Solsen]

Isa yderligere svækket og oplivning af spekulationer om dara sc i solide. Herudover validering af platformene. Ikke en dårlig dag !

[Sukkeralf]

For Ena we also need to see how many patients that are AXL positive

[E_L]

@Solsen on your earlier Nordea comment; it is at 4h:31 in the presentation; apparantly they are developping a 'steroid sparing regimen' to be used with Dara and they indeed needed SC to do that

[E_L]

they also mention giving Dara in relation to CAR-t

[GeorgeBest]

Tak for forklaringer til, Solsen, Sukkeralf og EL...

[Solsen]

Could I ask you EL for the link to JNJ update ?

[E_L]

10:41

[Solsen]

Thanks !

[Tandfeen-2]

Har man for mange Genmab aktier når ens humør påvirkes af aktiekursen ?

[Solsen]

Nej det gør jo livet mere indholdsrigt

[Solsen]

Svinger mellem beruselse og søvnløse nætter. Det er ikke alle der oplever det ..

[Parasitism]

Jeg har ofte de samme tanker Tandfeen.

[Parasitism]

Genmab udgør også 99,4 % af mine aktier

[transalp]

Det er jo mere end halvdelen, Parasitism..

[nohope]

Well, I´m disappointed over the Ena trial, even though it is "only" safety/dose they are testing.

[E_L]

I understand. I am not worried yet, I think we need to wait for H2 for more data. From Q&A:

[E_L]

Andrew Carlsen First of all no setbacks in AXL...
Andrew Carlsen Enapotamab (Humax-Axl) continues to be a program that we are very excited about. It
should be noted that Enapotamab is the asset that is progressed the furthest after
Tisotumab and we expect data at ASCO from the Ph I dose escalation study in
NSCLC and in H219 we should get meaningful data from the expansion cohort.

[Parasitism]

Det er en kende mere end halvdelen, men jeg har faktisk ofte tænkt over, om jeg skulle reducerer i dem - på ingen måde fordi, at jeg ikke tror på fremtiden, men fordi det påvirker mit humør både op og ned.